BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-352@pharmaconomics
DTSTAMP:20260707T021914Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:ANAB PDUFA — imsidolimab
DESCRIPTION:The FDA's approval decision on imsidolimab for generalized pustular psoriasis (GPP) is due Dec 12\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm\n\nTrack it: https://www.pharmaconomics.com/e/352
URL:https://www.pharmaconomics.com/e/352
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ANAB catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR